Abstracts tagged "transcription factor and transcriptional regulation"

Abstract Number: 1566 • 2016 ACR/ARHP Annual Meeting
Histone Lysine Methylation and STAT3 Differentially Regulate Constitutive and IL-6-Induced MMPs Gene Activation in Rheumatoid Arthritis Synovial Fibroblasts
Yasuto Araki^1,2, Takuma Tsuzuki Wada^2,3, Yoshimi Aizaki^1,2, Kazuhiro Yokota¹, Hiroshi Kajiyama¹, Yu Funakubo Asanuma¹, Kojiro Sato¹, Hiromi Oda⁴ and Toshihide Mimura^1,2, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Project Research Division, Research Center for Genomic Medicine, Saitama Medical University, Saitama, Japan, ³Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma, Japan, ⁴Orthopedic Surgery, Faculty of Medicine, Saitama Medical Univeristy, Morohongo Moroyama, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that causes progressive joint destruction. In spite of the modern medications, including biologic reagents, it…
Abstract Number: 1888 • 2013 ACR/ARHP Annual Meeting
Transcriptional Regulation Of Peptidylarginine Deiminase Type IV: Implications For Rheumatoid Arthritis
Ali Abbas¹, Kevin Le¹, Virginia Pimmett¹, David A. Bell², Ewa Cairns² and Rodney P. DeKoter¹, ¹Microbiology and Immunology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ²Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
Background/Purpose: High titers of anti-citrullinated protein/peptide antibodies (ACPA) have been detected in sera of rheumatoid arthritis (RA) patients, implicating citrullinating enzymes in the pathogenesis of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].